AI Radiomics: The Future of Metabolic and Heart Risk Detection

A Glimpse into the Next Frontier

Artificial intelligence is reshaping how we understand health. Traditional CT and MRI scans have long helped doctors spot tumors, fractures, or organ changes. Yet these same images hold far more information than the human eye can see. Through a field known as radiomics, computers can now extract thousands of hidden data points such as textures, densities, and patterns that reveal early metabolic and cardiovascular risk.

While these technologies are still emerging and not yet widely available or covered by insurance, their promise is transformative. They may soon allow physicians to read imaging like lab results, turning static pictures into dynamic health biomarkers.

1. The Promise of AI Liver Fat Mapping

Radiomics can identify microscopic changes in liver fat long before routine labs show abnormalities. By analyzing subtle variations in pixel intensity, AI can estimate hepatic fat fraction and even detect early inflammation or fibrosis risk.

In the near future, such technology could:

• Quantify total liver fat automatically during any abdominal CT or MRI.
• Track changes in liver health as weight, glucose, and lipids improve.
• Help identify individuals at risk of nonalcoholic fatty liver disease before symptoms arise.

This approach could shift care from reactive treatment to true prevention, where clinicians address early dysfunction years before disease appears.

2. Seeing Visceral Fat as a Metabolic Organ

Not all fat behaves the same. Visceral fat (the “bad” fat), which surrounds the abdominal organs, acts like a gland that releases inflammatory molecules and drives insulin resistance. AI analysis of standard CT images can already estimate this fat precisely while also distinguishing it from subcutaneous fat (the “good” fat) and assessing muscle quality at the same time.

Future uses may include:

• Monitoring metabolic health more accurately than weight or BMI.
• Identifying patients whose hidden fat burden explains high ApoB or triglyceride levels.
• Predicting hypertension, diabetes, or cardiovascular events with higher precision.

As algorithms improve, these metrics may become routine and turn imaging into a central metabolic monitoring tool.

3. Smarter Heart Imaging and Plaque Biology

Coronary CT angiography (CCTA) already provides a detailed view of arteries. AI radiomics goes a step further by measuring plaque texture, density, and even the inflammation of fat around vessels, known as perivascular adipose tissue. These subtle features may reveal which plaques are stable and which are vulnerable to rupture.

In coming years, this could mean:

• Better prediction of heart attacks before they happen.
• Personalized treatment intensity based on plaque biology rather than cholesterol numbers.
• Combining imaging data with ApoB, Lp(a), and hs-CRP for an integrated risk model.

Such capabilities would help doctors match the right therapy, whether GLP-1, SGLT2, or PCSK9 agents, to each patient’s unique vascular biology.

4. The Power of Integration: Imaging Meets Lab Data

Radiomics becomes most powerful when combined with advanced blood biomarkers. Imaging captures structural change while labs capture biochemical behavior. When these insights are layered together, they form a complete map of cardiometabolic health.

Imagine a near-future visit where:

• A patient’s CT scan quantifies liver fat, visceral fat, and plaque composition.
• ApoB, Lp(a), and inflammatory markers provide molecular context.
• AI integrates both datasets to predict five- and ten-year risk, adjusting therapy dynamically.

This is the precision-prevention model that medicine is moving toward, one where data guides decisions instead of intuition alone.

Summary Table: How AI Radiomics May Transform Prevention

Domain	Current Understanding	AI Radiomics Vision	Clinical Readiness
Liver Fat (Hepatic Steatosis)	Detected late by ultrasound or elevated ALT/AST	Quantifies liver fat on routine MRI or CT, detecting early metabolic dysfunction	Research stage; limited to academic centers
Visceral and Abdominal Fat	Estimated by BMI or waist size	Measures deep fat distribution and muscle quality for better risk prediction	Emerging; pilot validation studies
Coronary and Aortic Plaque	Calcium score shows only calcified lesions	Evaluates plaque texture, vulnerability, and vessel inflammation	Active trials; early clinical testing
Epicardial Fat (Heart Fat)	Not routinely measured	Uses CT radiomics to assess inflammatory activity near coronary arteries	Research phase; promising for future integration
Integration with ApoB and Lp(a)	Blood markers and imaging interpreted separately	AI platforms combine imaging biomarkers and labs for unified risk scoring	Concept stage; under development
Insurance and Accessibility	Routine CT/MRI covered only for structural evaluation	Radiomic analytics not yet reimbursed; expected to expand as evidence grows	Not yet covered; future adoption likely
Patient Benefit Outlook	Delayed detection, reactive treatment	Earlier identification of risk, personalized prevention, dynamic tracking	High long-term potential; pending standardization

This table summarizes the transition from current practice to the next generation of precision diagnostics. Radiomics connects imaging and lab data to uncover disease before symptoms appear. Though it remains largely a research tool, it represents the direction of modern cardiometabolic care, by blending together structure, function, and biochemistry into a single, predictive model.

Practical Realities and Current Limitations

Today, these tools remain largely in academic centers and pilot research programs. They require standardized imaging, regulatory approval, and insurance adoption before they can be used routinely. Yet understanding them now prepares patients and clinicians for what comes next.

For the moment, proven steps remain essential:

• Lower ApoB and Lp(a) through optimized therapy.
• Reduce visceral fat with sustainable nutrition, activity, and metabolic support.
• Keep inflammation low through lifestyle and medication synergy.

When radiomics enters practice, it will amplify these core strategies rather than replace them.

Preparing Patients for the Next Era

Forward-thinking care means staying ready to adopt the most useful innovations once they are validated and accessible. At our practice in Montgomery County, Maryland, and through virtual care, we follow this science closely. Our goal is to integrate these tools when they become clinically available and covered, ensuring that each patient benefits safely and meaningfully from technology designed to predict disease rather than simply treat it.

For patients engaged in prevention today, radiomics represents hope: a future where every scan holds metabolic insight, every image offers feedback, and precision replaces uncertainty.

Key Takeaway

AI radiomics stands at the threshold of clinical reality. Although not yet part of everyday practice, it signals a shift toward earlier detection, deeper precision, and personalized prevention. By merging what we see on imaging with what we measure in blood, medicine will soon connect structure, metabolism, and outcomes within one unified view, protecting heart, liver, and life itself.